Добавлены профессиональными переводчиками и компаниями и на основе веб-страниц и открытых баз переводов.
xarelto er kontraindiceret til patienter med leversygdom, der medfører koagulationsdefekt og en klinisk relevant blødningsrisiko.
xarelto is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk.
xarelto er kontraindiceret til patienter med leversygdom, der er forbundet med koagulationsdefekt og en klinisk relevant blødningsrisiko.
xarelto is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk.
granolocytopeni, hæmolytisk anæmi, autoimmun hæmolytisk anæmi, hæmolyse, hyperkoagulation, koagulationsdefekt, monocytopeni, leukocytose, lymfadenopati
febrile neutropenia, pancytopenia, leucopenia*, lymphopenia* granulocytopenia, haemolytic anaemia, autoimmune haemolytic anaemia, haemolysis, hypercoagulation, coagulopathy, monocytopenia, leucocytosis, lymphadenopathy
xarelto kan anvendes med forsigtighed hos cirrosepatienter med moderat nedsat leverfunktion (child pugh b), hvis det ikke er forbundet med koagulationsdefekt (se pkt.
xarelto may be used with caution in cirrhotic patients with moderate hepatic impairment (child pugh b) if it is not associated with coagulopathy (see sections 4.4 and 5.2).
der findes ingen informationer om sikkerhedsprofilen af avastin hos patienter med kongenit hæmoragisk diatese, erhvervet koagulationsdefekt eller hos patienter, som modtager fuld dosis af antikoagulantia for behandling af tromboemboli før behandlingen med avastin påbegyndes, da sådanne patienter ikke indgik i de kliniske studier.
there is no information on the safety profile of avastin in patients with congenital bleeding diathesis, acquired coagulopathy or in patients receiving full dose of anticoagulants for the treatment of thromboembolism prior to starting avastin treatment, as such patients were excluded from clinical trials.
der findes ingen informationer om sikkerhedsprofilen af avastin hos patienter med kongenit hæmoragisk diatese, erhvervet koagulationsdefekt eller hos patienter, som får fuld dosis af antikoagulantia for behandling af tromboemboli, før behandlingen med avastin påbegyndes, da sådanne patienter ikke indgik i de kliniske studier.
there is no information on the safety profile of avastin in patients with congenital bleeding diathesis, acquired coagulopathy or in patients receiving full dose of anticoagulants for the treatment of thromboembolism prior to starting avastin treatment, as such patients were excluded from clinical trials.
febril neutropeni, pancytopeni, leukopeni *, lymfopeni * ikke almindelig:granolocytopeni, hæmolytisk anæmi, autoimmun hæmolytisk anæmi, hæmolyse, hyperkoagulaion, koagulationsdefekt, monocytopeni, leukocytose, lymfadenopati
febrile neutropenia, pancytopenia, leucopenia*, lymphopenia* granulocytopenia, haemolytic anaemia, autoimmune haemolytic anaemia, haemolysis, hypercoagulation, coagulopathy, monocytopenia, leucocytosis, lymphadenopathy